Metformin carbon dots enhance neurogenesis and neuroprotection in Alzheimer's disease: A potential nanomedicine approach
Source abstract
Abstract
Alzheimer's disease (AD) is characterized by progressive cognitive decline due to neuronal damage and impaired neurogenesis. Preserving neuronal integrity and stimulating neurogenesis are promising therapeutic strategies to combat AD-related cognitive dysfunction. In this study, we synthesized metformin carbon dots (CMCDs) using a hydrothermal method with metformin hydrochloride and citric acid as precursors. Notably, we found that CMCDs were significantly more effective than metformin in promoting the differentiation of neural stem cells (NSCs) into functional neurons under amyloid-beta (Aβ) conditions. Moreover, CMCDs fostered NSCs proliferation, enhanced neurogenesis, reduced Aβ deposition, and inhibited glial cell activation. We also examined neuronal structure by assessing Map2/NF-H/PSD95/SYN expression in the hippocampus, finding that CMCDs robustly strengthened neuronal structure. These results suggest that CMCDs can cognitive dysfunction in AD and promote the proliferation and neurogenesis of NSCs, as well as ameliorate neuronal injury. Hence, CMCDs emerge as promising candidates for AD therapy, demonstrating superior efficacy compared to metformin alone, and offering novel insights into small molecule drug interventions for AD.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Carbon and Quantum Dots Applications · Graphene and Nanomaterials Applications · Nanocluster Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (54)
Show source-provided references
1. J. Alzheimers Assoc. · 2023 · 19 · 1598
2. Glucose metabolism, neural cell senescence and Alzheimer's disease10.3390/ijms23084351 ↗
3. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease10.1172/JCI0216783 ↗
4. Mitochondrial dysfunction as a driver of cognitive impairment in Alzheimer's disease10.3390/ijms22094850 ↗
5. Deciphering the roles of metformin in Alzheimer's disease: a snapshot10.3389/fphar.2021.728315 ↗
6. Pathophysiological aspects and therapeutic armamentarium of Alzheimer's disease: recent trends and future development10.1007/s10571-023-01408-7 ↗
7. Ning
8. What is adult hippocampal neurogenesis good for?10.3389/fnins.2022.852680 ↗
9. Neurovascular coupling in the dentate gyrus regulates adult hippocampal neurogenesis10.1016/j.neuron.2019.05.045 ↗
10. Adult hippocampal neurogenesis and its impairment in Alzheimer's disease10.24272/j.issn.2095-8137.2021.479 ↗
11. Adult hippocampal neurogenesis in aging and Alzheimer's disease10.1016/j.stemcr.2021.01.019 ↗
12. Promoting endogenous neurogenesis as a treatment for Alzheimer's disease10.1007/s12035-022-03145-2 ↗
13. Alzheimer's disease-associated U1 snRNP splicing dysfunction causes neuronal hyperexcitability and cognitive impairment10.1038/s43587-022-00290-0 ↗
14. An App knock-in rat model for Alzheimer's disease exhibiting Aβ and tau pathologies, neuronal death and cognitive impairments10.1038/s41422-021-00582-x ↗
15. Repurposing of phyto-ligand molecules from the honey bee products for Alzheimer's disease as novel inhibitors of BACE-1: small molecule bioinformatics strategies as amyloid-based therapy10.1007/s11356-023-25943-4 ↗
16. S. Datta, A. Gajbhiye, S. Patil, Pegylated chitosan biodegradable nanoparticles delivery of salvia officinalis and melissa officinalis for enhanced brain targeting, Curr. Nanomedicine 13 (n.d.) 1–13.
17. Exploring the pharmacological potential of metformin for neurodegenerative diseases10.3389/fnagi.2022.838173 ↗
18. Metformin-enhanced cardiac AMP-activated protein kinase/atrogin-1 pathways inhibit charged multivesicular body protein 2B accumulation in ischemia–reperfusion injury10.3389/fcell.2020.621509 ↗
19. Li
20. Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus10.1186/s12933-020-01202-5 ↗
21. Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease10.1080/13543784.2023.2196010 ↗
22. Metformin treatment attenuates tau seeding in neuritic plaques - Zhao - 2020 - Alzheimer’s & Dementia - Wiley Online Library, (n.d.). https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.041470 (accessed November 12, 2023).
23. Metformin improves cognition of aged mice by promoting cerebral angiogenesis and neurogenesis10.18632/aging.103693 ↗
24. Metformin restores hippocampal neurogenesis and learning and memory via regulating gut microbiota in the obese mouse model10.1016/j.bbi.2021.02.011 ↗
25. Deciphering the roles of metformin in Alzheimer's disease: a snapshot
26. Metformin improves learning and memory in the SAMP8 mouse model of Alzheimer's disease10.3233/JAD-181240 ↗
27. Metformin restores cognitive dysfunction and histopathological deficits in an animal model of sporadic Alzheimer's disease10.1016/j.heliyon.2023.e17873 ↗
28. Understanding the uptake of nanomedicines at different stages of brain cancer using a modular nanocarrier platform and precision bispecific antibodies10.1021/acscentsci.9b01299 ↗
29. Systemic dendrimer-drug nanomedicines for long-term treatment of mild-moderate cerebral palsy in a rabbit model10.1186/s12974-020-01984-1 ↗
30. Targeting nanoparticles to the brain by exploiting the blood-brain barrier impermeability to selectively label the brain endothelium10.1073/pnas.2002016117 ↗
31. Combinational effects of active targeting, shape, and enhanced permeability and retention for cancer theranostic nanocarriers10.1021/acsami.8b21609 ↗
32. Carbon dots: a new type of carbon-based nanomaterial with wide applications10.1021/acscentsci.0c01306 ↗
33. Carbon dots: classification, properties, synthesis, characterization, and applications in health care—an updated review (2018–2021)10.3390/nano11102525 ↗
34. E.S. Seven, Y.B. Seven, Y. Zhou, S. Poudel-Sharma, J.J. Diaz-Rucco, E. Kirbas Cilingir, G.S. Mitchell, J.D. Van Dyken, R.M. Leblanc, Crossing the blood–brain barrier with carbon dots: uptake mechanism and in vivo cargo delivery, Nanoscale Adv. 3 (n.d.) 3942–3953. https://doi.org/10.1039/d1na00145k.10.1039/D1NA00145K ↗
35. Metformin derived carbon dots: highly biocompatible fluorescent nanomaterials as mitochondrial targeting and blood-brain barrier penetrating biomarkers10.1016/j.jcis.2021.02.058 ↗
36. Significance of native PLGA nanoparticles in the treatment of Alzheimer's disease pathology
37. Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease10.1007/s00210-021-02096-0 ↗
38. Nontoxic amphiphilic carbon dots as promising drug nanocarriers across the blood–brain barrier and inhibitors of β-amyloid10.1039/C9NR08194A ↗
39. Updates on mouse models of Alzheimer's disease
40. Adult hippocampal neurogenesis in Alzheimer's disease: a roadmap to clinical relevance10.1016/j.stem.2023.01.002 ↗
41. Carbon dots: synthesis, formation mechanism, fluorescence origin and sensing applications10.1039/C8GC02736F ↗
42. Microwave-assisted synthesis of carbon dots and their applications10.1039/C9TC01640F ↗
43. Carbon nitride dots: a selective bioimaging nanomaterial10.1021/acs.bioconjchem.8b00784 ↗
44. Carbon dots produced via space-confined vacuum heating: maintaining efficient luminescence in both dispersed and aggregated states10.1039/C8NH00247A ↗
45. Discovery of a dual-action small molecule that improves neuropathological features of Alzheimer's disease mice10.1073/pnas.2115082119 ↗
46. Isolation of neural stem cells from the embryonic mouse Hippocampus for in vitro growth or engraftment into a host tissue10.21769/BioProtoc.3165 ↗
47. Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma10.1038/s41467-021-26297-6 ↗
48. Gold nanostrip array‐mediated wireless electrical stimulation for accelerating functional neuronal differentiation10.1002/advs.202202376 ↗
49. Carbon nanotube–hydrogel composites facilitate neuronal differentiation while maintaining homeostasis of network activity10.1002/adma.202102981 ↗
50. Dysregulated expression of monoacylglycerol lipase is a marker for anti-diabetic drug metformin-targeted therapy to correct impaired neurogenesis and spatial memory in Alzheimer's disease10.7150/thno.44962 ↗
51. Physiological synaptic activity and recognition memory require astroglial glutamine10.1038/s41467-022-28331-7 ↗
52. Seed-induced Aβ deposition alters neuronal function and impairs olfaction in a mouse model of Alzheimer's disease10.1038/s41380-022-01686-5 ↗
53. Role of chronic neuroinflammation in neuroplasticity and cognitive function: a hypothesis10.1002/alz.12610 ↗
54. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?10.1038/s41582-020-00435-y ↗